Format

Send to

Choose Destination
Int J Neuropsychopharmacol. 2010 Jul;13(6):793-8. doi: 10.1017/S1461145710000167. Epub 2010 Mar 3.

Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes.

Author information

1
Neurogenetics Section, Centre for Addiction and Mental Health, Toronto, ON, Canada.

Abstract

Antipsychotic drugs are the best means available for symptomatically treating individuals suffering from schizophrenia; however, there is a significant variability in clinical response to these psychotropic medications. Previous findings connect oxytocin (OXT) with schizophrenia and antipsychotic action. Therefore, we evaluated if OXT and OXT receptor (OXTR) genes might play a role in the symptom severity and clozapine treatment response in schizophrenia subjects. The rs2740204 variant in the OXT gene was significantly associated with treatment response (after 1000 permutations p=0.042) and nominally associated with negative symptoms in our sample. Furthermore, variants in the OXTR were nominally associated with severity of overall symptoms accessed using the Brief Psychiatric Rating Scale (rs237885, rs237887) as well as on the improvement of the positive symptoms (rs11706648, rs4686301, rs237899). Additional association studies in independent samples will be able evaluate whether OXT and OXTR genes are truly playing a role in the clozapine treatment outcome.

PMID:
20196918
DOI:
10.1017/S1461145710000167
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center